Woojung Bio Co., Ltd. (CEO Hee-Jeong Cheon) announced on the 30th that it has signed a strategic business agreement (MOU) with Galaxy Co., Ltd. (CEO Cha-Ok Seok), an artificial intelligence (AI)-based new drug development company, for the development of therapeutic agents.
This collaboration is part of Woojung Bio's ongoing open innovation project. The two companies will leverage their respective core competencies to accelerate the development of antibody-based therapeutics. Woojung Bio boasts experience and infrastructure in the non-clinical CRO (contract research organization) field, while Galaxy possesses an AI-based new drug candidate design platform.
Through this agreement, the two companies plan to: establish a rapid non-clinical validation system for AI-based new drug candidates; discover new targets and conduct joint research and development; share existing information and networks; and conduct joint R&D utilizing both companies' infrastructure. Through this, they aim to enhance the accuracy and efficiency of AI-based new drug development and establish a virtuous cycle of R&D cooperation.
Galux possesses de novo antibody design technology through its proprietary "GaluxDesign" platform. Unlike traditional bioimmunological or antibody library-based approaches, this technology allows for precise consideration of molecular structure and function from the design stage. This allows access to complex targets such as GPCRs and ion channels, and the company is recognized as one of the few global companies with a proven track record of successful de novo antibody design.
Woojung Bio expects this agreement to enhance its non-clinical services and expand its collaboration capabilities with AI-based drug development companies. The company plans to continue expanding its business scope through open collaborations with various technology-based companies.
“It is a meaningful step forward that antibodies designed using AI have actually been verified at the non-clinical stage,” said Galaxy CEO Seok-Cha Ok. “Our collaboration with Woojung Bio will be an important opportunity to realize the process of AI new drug design technology leading to the development of actual therapeutics.”
Woojung Bio CEO Hee-Jeong Cheon said, “As the new drug development cycle is getting shorter due to the introduction of new technologies such as AI, securing precise and rapid non-clinical data is becoming more important,” and “Through this collaboration, we will establish an advanced non-clinical service system and strengthen our competitiveness in the new drug development field through continuous open innovation.”
- See more related articles
You must be logged in to post a comment.